Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 59Leukemia 55Lymphoma, Non-Hodgkin 45Lymphoma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 43Multiple Myeloma 42Hodgkin Disease 38Hematologic Neoplasms 35Myeloproliferative Disorders 24Melanoma 22Lymphoma, Mantle-Cell 18Recurrence 17Lymphoma, Follicular 17Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Primary Myelofibrosis 14Lymphoma, B-Cell 14Burkitt Lymphoma 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, B-Cell, Marginal Zone 13Leukemia, Myelomonocytic, Chronic 13Leukemia, Biphenotypic, Acute 13Graft vs Host Disease 13Hematologic Diseases 12Anemia, Aplastic 11Skin Neoplasms 10Ovarian Neoplasms 10

Interventions

fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Peripheral Blood Stem Cell Transplantation 2Cyclosporins 2Cyclosporine 2Cyclophosphamide 2venetoclax 1ruxolitinib 1letermovir 1ibrutinib 1fludarabine 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Sirolimus 1Mitoxantrone 1Melphalan 1Lisaftoclax 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Cytarabine 1Carmustine 1Biopsy 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Prolymphocytic, T-Cell × fludarabine × Clear all
NCT01186640 2022-01-05

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

German CLL Study Group

Phase 2 Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡